1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20166
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsiara, S. N.en
dc.contributor.authorKapsali, H. D.en
dc.contributor.authorChaidos, A.en
dc.contributor.authorChristou, L.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:05:15Z-
dc.date.available2015-11-24T19:05:15Z-
dc.identifier.issn0001-5792-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20166-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntibodies, Monoclonal/administration & dosageen
dc.subjectAntibodies, Monoclonal, Murine-Deriveden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration &en
dc.subjectdosage/*therapeutic useen
dc.subjectDrug Resistance, Neoplasmen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPentostatin/administration & dosageen
dc.subjectRecurrenceen
dc.subjectRemission Inductionen
dc.subjectSalvage Therapy/*methodsen
dc.subjectSurvival Rateen
dc.subjectTreatment Outcomeen
dc.titleTreatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximaben
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1159/000077550-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15153709-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000077550-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2004-
heal.abstractBACKGROUND: Patients with chronic lymphocytic leukemia (CLL) are sometimes resistant to treatment or relapse soon after the administration of the currently available frontline therapy including chlorambucil-prednisolone CHOP and fludarabine. We report the beneficial effect of an alternative chemotherapeutic regimen containing 2'-deoxycoformycin (pentostatin) and the monoclonal antibody anti-CD20 (rituximab) in 5 patients with resistant/relapsing CLL. PATIENTS: Five patients (4 men and 1 woman) with CLL at stage C, according to Binet's classification, were included in the therapeutic protocol. The median age of the patients was 76 years (range 57-84 years). Previous treatment consisted of chlorambucil-prednisolone, fludarabine, and CHOP. The current regimen comprised six 2-week cycles of pentostatin, 4 mg/m(2) i.v., combined with four cycles of rituximab, in a dose of 375 mg/m(2), every other week. RESULTS: Three patients responded to therapy, 2 achieved complete remission and 1 a partial response. Two patients did not respond to treatment. Toxicity was mild and well tolerated. The median survival duration of the responders was 19 months. These promising results suggest that salvage therapy with a combination regimen including pentostatin and rituximab may have a beneficial effect in patients with resistant/relapsing CLL.en
heal.journalNameActa Haematolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons